Skip to main content
GDRX logo

GDRX · GoodRx Holdings, Inc.

Track GDRX — free
$3.36 -0.11 (-3.17%) At close · Nov 18
Market Cap
$1.15B
Shares
341.15M
Volume · Nov 18 659.27K Avg daily vol (3M) 1.14M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.36 Open$3.47 Day$3.36–3.52 52W close$1.87–3.80 Avg vol 30d1.1M Short int3.6M · 1.0% of shares · 3.0d Short vol56% Last earningsAug 6, 2026 DataSep 2020–Nov 2026 Filing10-Q · Aug 5

Latest documents

2026
Nov 10
Late filing notice NT 10-Q
Quarterly filing delayed amid revenue restatement and control weaknesses

GoodRx Holdings, Inc. said certain financial statements should no longer be relied upon after revenue recognition errors undercounted Pharma Direct revenue. It delayed its quarter ended September 30, 2026 filing and expects one or more material weaknesses in internal controls.

3 source passages
GoodRx Holdings, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense. This error resulted in an understatement of Pharma Direct revenue and total revenue in each Affected Period. The Company currently expects to report that one or more material weaknesses in internal control over financial reporting existed as of March 30, 2026, June 30, 2026, and September 30, 2026. Open the document at this passage
Nov 2
Current report 8-K Events of Oct 27
Pharma Direct revenue understatement prompts financial statement non-reliance

GoodRx Holdings, Inc. said statements for periods ended March 31, 2026 and June 30, 2026 should no longer be relied upon due to understated Pharma Direct revenue. Amended filings are planned, and material weaknesses in internal control are expected.

Earlier financial statements no longer reliable
3 source passages
On October 27, 2026, the Audit and Risk Committee of the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), after discussion with management of the Company and the Company’s independent registered public accounting firm, KPMG LLP (“KPMG”), concluded that the Company’s condensed consolidated financial statements for the fiscal quarter and year-to-date periods ended March 31, 2026 and June 30, 2026 (collectively, the “Affected Periods”) should no longer be relied upon due to the understatement of Pharma Direct revenue. The Company is working to complete the restatement of its condensed consolidated financial statements for the Affected Periods by filing amended Forms 10-Q for such periods as soon as practicable. The Company currently expects to report that one or more material weaknesses in internal control over financial reporting existed as of the end of each Affected Period. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$785.23M
Trailing 12 months
Net income (TTM)
$16.25M
Trailing 12 months
Revenue growth YoY
-1.3%
Year over year
Operating margin
9.5%
Trailing 12 months
P / E (TTM)
84.0
Trailing earnings · reciprocal yield 1.2%
FCF yield
17.2%
TTM · current market cap
Return on invested capital
3.5%
Trailing 12 months
Net cash
−$190.47M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.5%
Year over year · fewer shares
Price change (1Y)
+20.4%
Trailing year
Short interest
1.0%
Latest settlement · 3.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. GoodRx reported Q2 revenue of $200.4 million, down 1% year-over-year, as Pharma Direct (+76%) and Subscription (+39%) growth was offset by a 26% drop in prescription transactions revenue and a CFO transition; the company raised its full-year 2026 revenue outlook to $790–$805 million and Adjusted EBITDA to $240–$250 million.

Bullish
  • + Pharma Direct revenue grew 76% year-over-year to $61.6 million, with full-year PharmaDirect now expected to grow more than 70%.
  • + Subscription revenue grew 39% year-over-year to $28.5 million and subscription plans rose 14%, supported by the May launch of GoodRx Companion.
  • + Company raised full-year 2026 Adjusted EBITDA guidance to $240–$250 million.
  • + Net cash provided by operating activities rose to $80.8 million in Q2 from $49.6 million a year earlier, with $296.1 million of cash on hand.
Bearish
  • − Total revenue declined 1% year-over-year to $200.4 million.
  • − Prescription transactions revenue fell 26% year-over-year to $106.4 million on declining MACs and deliberate shift toward subscriptions.
  • − Net income declined to $8.5 million from $12.8 million and Adjusted Net Income fell to $26.8 million from $33.9 million.
  • − Adjusted EBITDA margin contracted to 31.8% from 34.2% as Adjusted EBITDA fell to $63.7 million from $69.4 million.
  • − CFO transition: Chris McGinnis departed as CFO and was replaced by Justin Fingler, adding leadership risk during a business model pivot.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +16%
above
Price vs 50-day avg −2%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 77%
mid-range
Momentum
relative strength
Strong
1-month return −6%
trailing
6-month return +15%
trailing
YTD return +24%
this year
Relative strength +19%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.05% of shares out · ▼ -2.7% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
182 holders — mid 3-yr range
Squeeze score 40
elevated · 0–100
Fundamentals
Strong
Revenue growth +1%
Y/Y
EPS growth +125%
Y/Y
Free cash flow $164.4M
Valuation P/E 84
rich
Buyback $60.3M
remaining
Balance sheet $226.4M
net debt
Quant / Vol
risk profile
Very High
Volatility 56%
annualized · 1-yr
Max drawdown −36%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the Earnings Call filed Aug 6, 2026
Revenue · full year Maintained $790M – $805M
Aug 5, 2026 $790M – $805M changed to Aug 6, 2026 $790M – $805M
prior FY $796.85M midpoint +0.1% Y/Y
Adjusted EBITDA · full year Non-GAAP Maintained $240M – $250M
Aug 5, 2026 $240M – $250M changed to Aug 6, 2026 $240M – $250M
Previous outlook earlier release · from the 8-K filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA · FY 2026 at least $235M
Guided vs delivered · last 8 settled
Revenue5 1Q 2024
guided $195M – $198M
$197.88M In line
Revenue 4Q 2023
guided $188M – $194M
$196.64M Beat +3.0%
Revenue FY 2023
guided $742M – $748M
$750.27M Beat +0.7%
Total Revenue 3Q 2023
guided $186M – $190M
$179.96M Miss −4.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+16% Bullish
Price vs 50-day avg
−2% Neutral
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
77% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.05% of shares out · ▼ -2.7% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
182 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 77% Range high $4
vs 200-day avg +16% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted Earnings Per Share non-GAAP $0.08 Three Months Ended June 30, 2026 —
Adjusted EBITDA non-GAAP $122.01M Six Months Ended June 30, 2026 —
Adjusted EBITDA Margin non-GAAP 30.9% Six Months Ended June 30, 2026 —
Adjusted Net Income non-GAAP $49.83M Six Months Ended June 30, 2026 —
Adjusted Net Income Margin non-GAAP 12.6% Six Months Ended June 30, 2026 —
Monthly Active Consumers 5M Three Months Ended June 30, 2026 —
Subscription plans 764K As of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GDRX
GoodRx Holdings, Inc.
this stock
$1.15B +24.0% +0.6% 84.0 1.0%
VEEV
Veeva Systems Inc
$44.88B +24.2% +28.1% 45.4 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$13.60B +82.5% +28.2% 37.1 5.8%
TEM
Tempus AI, Inc.
$11.60B +7.7% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
182
% held
35.0%
Net QoQ
+678.0K sh
Top holder
Francisco Partners Manage…
Held Float
View
Held by Funds
Fund positions
80
View
Short & Settlement
Short Interest Falling
Shares short
3.6M
Days to cover
3.0d
Change
-100.2K sh
View
Short Volume
Short vol %
56%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
790
Value
$2.7K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
29.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$796.9M
Net income (FY)
$30.4M
EPS diluted
$0.09
View
Buybacks
Authorized
$450.0M
Remaining
$60.3M
Spent Remaining
View
Filings
SEC Filings
Latest
NT 10-Q
Filed
Nov 10, 2026
This year
19

GoodRx Holdings, Inc. said certain financial statements should no longer be relied upon after revenue recognition errors undercounted Pharma Direct revenue. It delayed its quarter ended September 30, 2026 filing and expects one or more material weaknesses in internal controls.

View
Proposed Sales
Value
$10.3M
Shares
2.8M
Filed
Aug 19, 2026
View
Exempt Offerings
Offering
$10.3M
Filed
Jun 25, 2020
View
Earnings & Events
Webcasts
Last webcast
Aug 6, 2026
View
Investor Relations
Latest news
GoodRx Brings Prescription Pricin…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
GDRX -8.0% -5.9% +15.1% -3.7% +24.0%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -4.1% -0.3% +18.5% -0.3% +16.9%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$450.00M
Spent (derived)
$389.70M
Remaining
$60.30M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1809519 CUSIP 38246G108 13F (30d) 191 filings 174 filers Visit website Investor relations